Q3 – Talk Bio

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

2 weeks ago talkbio0Tagged Capitalization, clinical-stage biopharma, development aspects, exophthalmos producing substance, financial results, Impaired, Market, net loss, Nkarta, Operating expenses, Q3, research

Nkarta; Q3 2025 financial results; net loss; operating expenses; EPS; research and development; impairment; market capitalization; clinical-stage biopharma; corporate highlights

Puma Biotechnology Reports Third Quarter 2025 Financial Results

3 weeks ago talkbio0Tagged beat, Clinical Trials, EPS, exophthalmos producing substance, financial results, Neoplasms, Nerlynx sales, net income, Puma Biotechnology, Q3, Revenue Decline, revenue guidance

Puma Biotechnology; Q3 2025; financial results; EPS beat; revenue decline; Nerlynx sales; net income; oncology; clinical trials; revenue guidance

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

3 weeks ago talkbio0Tagged BEACON-IPF, cash reserves, Clinical Trials, development expenses, financial results, net loss, oncology program, Oxford Finance, Pliant Therapeutics, PLN-101095, Q3, research

Pliant Therapeutics; Q3 2025 financial results; PLN-101095; oncology program; BEACON-IPF trial; net loss; research and development expenses; cash reserves; Oxford Finance loan repayment

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

3 weeks ago talkbio0Tagged B-Cell Lymphomas, Business Update, Cancer Therapeutic Procedure, cash position, Clinical Trials, financial results, Immunome, net loss, pipeline update, Q3, RINGSIDE trial, therapeutic autologous dendritic cells, varegacestat

Immunome; Q3 2025; financial results; business update; pipeline update; cancer therapies; RINGSIDE trial; varegacestat; IM-1021; B-cell lymphoma; clinical trials; ADC; net loss; cash position

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

3 weeks ago talkbio0Tagged Autoimmune Diseases, cash runway, CIDP CAPTIVATE trial, claseprubart, Dianthus Therapeutics, DNTH212, expense, financial results, MaGic trial, Q3

Dianthus Therapeutics; Q3 2025 financial results; claseprubart; DNTH212; autoimmune disease; MaGic trial; CIDP CAPTIVATE trial; R&D expenses; net loss; $525M cash runway

Pfizer Cuts 11 R&D Programs amid Ongoing Revenue Declines and Cost Realignment Efforts

3 weeks ago talkbio0Tagged Cost Savings, COVID19 (disease), digital enablement, earnings, Pfizer, Q3, R&D, Revenue Decline, Seagen acquisition

Pfizer; R&D cuts; revenue decline; cost savings; Q3 2025 earnings; COVID-19 product sales; digital enablement; AI in R&D; Seagen acquisition

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

4 weeks ago talkbio0Tagged Biktarvy, cell therapy sales, financial results, Gilead Sciences, HIV franchise, Livdelzi, Q3, Tecartus, Trodelvy, Veklury, Yescarta, Yeztugo

Gilead Sciences; cell therapy sales; Q3 2025 financial results; HIV franchise; Yescarta; Tecartus; Biktarvy; Yeztugo; Livdelzi; Trodelvy; Veklury

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

4 weeks ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

United Imaging Healthcare Q3 2025 Results: Overseas Revenue Up 42% YoY

4 weeks ago talkbio0Tagged Global Expansion, Investments, Market, Medical Imaging, overseas, Q3, revenue growth, United Imaging Healthcare

United Imaging Healthcare; Q3 2025 results; overseas revenue growth; medical imaging; emerging markets; R&D investment; global expansion